

Freedom of Information request 206-21

Request

I am researching the incidence and treatment of breast cancer. I would greatly appreciate if you could answer the following two questions.

Q1. How many patients have you treated (using surgery, radiotherapy or any systemic anti-cancer therapy) in the last three months for:

- Breast cancer (any stage)
- Early breast cancer (both early-stage and locally advanced, inclusive of stages I-IIIc)
- Metastatic breast cancer (stage IV)

Q2. How many patients have been treated for breast cancer (any stage) in the past 3 months with the following systemic anti-cancer therapies:

- Abemaciclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole)
- Abemaciclib + Fulvestrant
- Anthracycline (e.g. doxorubicin or epirubicin) as a single agent
- Atezolizumab + Nab-paclitaxel/Paclitaxel
- Capecitabine as a single agent
- Carboplatin or Cisplatin as a single agent
- Eribulin as a single agent or in combination
- Everolimus + Exemestane
- Fluorouracil
- Fulvestrant as a single agent
- Lapatinib
- Neratinib
- Olaparib
- Palbociclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole)
- Palbociclib + Fulvestrant
- Pertuzumab + Trastuzumab + Docetaxel
- Platinum (e.g. carboplatin or cisplatin) as a single agent
- Ribociclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole)
- Ribociclib + Fulvestrant
- Talazoparib
- Taxane (e.g. docetaxel, paclitaxel, nab-paclitaxel) as a single agent
- Trastuzumab as a single agent or in combination
- Trastuzumab emtansine
- Any other active systemic anti-cancer therapy

Response

1. Within NHS Borders 132 patients have been treated for breast cancer in the last 3 months. We are unable to provide this data broken down by Early or Metastatic breast cancer as this data is not held, therefore under Section 17 we cannot provide.
2. The number of patients treated for the drugs outlined in the request in the past 3 months are below:

Abemaciclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole)	0
Abemaciclib + Fulvestrant	0
Anthracycline (e.g. doxorubicin or epirubicin) as a single agent	0
Atezolizumab +Nab-paclitaxel/Paclitaxel	0
Capecitabine as a single agent	9
Carboplatin or Cisplatin as a single agent	0
Eribulin as a single agent or in combination	0
Everolimus + Exemestane	0
Fluorouracil	0
Fulvestrant as a single agent	0
Lapatinib	0
Neratinib	<5
Olaparib	0
Palbociclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole)	15
Palbociclib + Fulvestrant	5
Pertuzumab + Trastuzumab + Docetaxel	<5
Platinum (e.g. carboplatin or cisplatin) as a single agent	0
Ribociclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole)	0
Ribociclib + Fulvestrant	0
Talazoparib	0
Taxane (e.g. docetaxel, paclitaxel, nab-paclitaxel) as a single agent	16
Transtuzumab as a single agent or in combination	14
Trastuzumab emtansine	<5
Any other active systemic	32

As the number of events in some areas are very small and in accordance with the Code of Practice for Official Statistics any number that is less than five, actual numbers and potentially identifiable information is withheld to help maintain patient confidentiality due to potential risk of disclosure. Further information is available in the ISD Statistical Disclosure Control Protocol.

If you are not satisfied with the way your request has been handled or the decision given, you may ask NHS Borders to review its actions and the decision. If you would like to request a review please apply in writing to, Freedom of Information Review, NHS Borders, Room 2EC3, Education Centre, Borders General Hospital, Melrose, TD6 9BS or foi.enquiries@borders.scot.nhs.uk.

The request for a review should include your name and address for correspondence, the request for information to which the request relates and the issue which you wish to be reviewed. Please state the reference number **206-21** on this request. Your request should be made within 40 working days from receipt of this letter.

If following this review, you remain dissatisfied with the outcome, you may appeal to the Scottish Information Commissioner and request an investigation of your complaint. Your request to the Scottish Information Commissioner should be in writing (or other permanent form), stating your name and an address for correspondence. You should provide the details of the request and your reasons for dissatisfaction with both the original response by NHS Borders and your reasons for dissatisfaction with the outcome of the internal review. Your application for an investigation by the Scottish Information Commissioner must be made within six months of your receipt of the response with which you are dissatisfied. The address for the Office of the Scottish Information Commissioner is, Office of the Scottish Information Commissioner, Kinburn Castle, Doubledykes Road, St Andrews, Fife.